#China #Suzhou #Innovent Biologics #IBI3055 #T Cell Engager

Innovent Biologics Unveils IBI3055 at Immune Resetting Summit 2026

Innovent Biologics, a leading biopharmaceutical company based in Suzhou, China, has made headlines at the 2026 Immune Resetting B-Cell Mediated & Beyond Summit in Boston. The company introduced its innovative tri-specific T-cell engager, IBI3055, designed to tackle various autoimmune diseases. This presentation highlighted groundbreaking preclinical data that showcases the therapeutic potential of this novel approach in immunology.

What is IBI3055?

IBI3055 is a unique therapeutic candidate that targets three essential molecules: CD19, B-cell maturation antigen (BCMA), and CD3. The design incorporates a novel “1+1+1” T-cell engager framework that aims to effectively mediate T-cell activation while minimizing non-specific immune responses through a technique known as CD3 masking.

This tri-specific antibody represents a significant advancement in the treatment of autoimmune diseases driven by B cells or plasma cells, offering a new approach that balances efficacy with a preferable safety profile. By focusing on precise T-cell activation, IBI3055 is expected to provide durable clinical benefits.

Key Benefits and Findings

During the oral presentation, several key findings from the preclinical studies were detailed:

• - Enhanced Cytotoxicity: IBI3055 demonstrated robust cytotoxicity against both CD19 and BCMA-positive cells, displaying efficacy comparable to mono-targeting T-cell engagers.
• - Deep Immune Cell Depletion: In models developed with human CD19/BCMA/CD3 transgenic mice, the treatment led to significant depletion of B cells and plasma cells across various compartments of the body, including peripheral blood, spleen, lymph nodes, and bone marrow.
• - Reduction in Immunoglobulin Levels: The studies indicated IBI3055's ability to substantially lower circulating immunoglobulin levels, a key factor in the pathophysiology of many autoimmune conditions.
• - Safety and Tolerability: Results from non-human primate studies suggested not only effective immune cell depletion but also favorable safety and tolerability profiles, making it a promising candidate for clinical use.

Vision for the Future

Dr. Huizhong Xiong, Vice President of Immunology at Innovent, emphasized the critical unmet needs in managing autoimmune diseases and the potential of innovative therapies like IBI3055. He stated, “There is an urgent need for therapies capable of inducing deep immune cell depletion and immune resetting to deliver durable clinical benefits.” His insights reflect the driving philosophy behind Innovent’s ongoing commitment to research and development in this space.

Innovent Biologics: A Commitment to Innovation

Founded in 2011, Innovent Biologics has established itself as a key player in the biopharmaceutical landscape, focusing on the development of affordable and high-quality medicines for diverse therapeutic areas, including oncology, autoimmune, cardiovascular, and metabolic diseases.

With 18 products currently in the market and several others in the pipeline—including 5 assets in pivotal clinical stages—Innovent’s collaborative approach with over 30 global healthcare organizations further exemplifies its commitment to advancing the biopharmaceutical industry.

This groundbreaking presentation at the Immune Resetting Summit underscores not only the possibilities that IBI3055 brings for individuals suffering from autoimmune conditions but also Innovent's dedication to pioneering new solutions for complex healthcare challenges. For more detailed information, visit their official website at www.innoventbio.com or follow them on LinkedIn and other social media platforms.